Chronic Lymphocytic Leukemia

Monica D. Mead, MD, discusses the clinical significance of the phase 3 MURANO trial in chronic lymphocytic leukemia.

Mazyar Shadman, MD, shares treatment considerations for patients with chronic lymphocytic leukemia.

Experts comment on the use of venetoclax-based therapy in treating chronic lymphocytic leukemia.

Experts Dr Stilgenbauer and Dr Ghia highlight and comment on the ECOG 1912 and iLLUMINATE trials.

Dr Stilgenbauer explains the ELEVATE-TN and ASCEND clinical trials; Dr Brown highlights the adverse effects seen with acalabrutinib.

Experts provide insight on the use of acalabrutinib in treating chronic lymphocytic leukemia.

Dr Brown provides a brief overview of data available that support the use of Bruton’s tyrosine kinase inhibitors in treating chronic lymphocytic leukemia; Dr Stilgenbauer comments on mitigating and managing adverse effects in the treatment of chronic lymphocytic leukemia.

Dr Ghia provides an in-depth conversation on the use of Bruton tyrosine kinase inhibitors in treating chronic lymphocytic leukemia.

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic lymphocytic leukemia.

January 26, 2021 - Acalabrutinib showed noninferior progression-free survival and a significantly lower incidence of atrial fibrillation versus ibrutinib in patients with high-risk chronic lymphocytic leukemia.

January 25, 2021 - The Japanese Ministry of Health, Labour and Welfare approved the BTK inhibitor acalabrutinib for use in adult patients with relapsed/refractory chronic lymphocytic leukemia, including small lymphocytic lymphoma

William G. Wierda, MD, PhD, discusses the latest CAPTIVATE findings in patients with chronic lymphocytic leukemia.

The experts comment on first-line treatment options in patients with chronic lymphocytic leukemia.

Dr Brown and Dr Ghia discuss the European Society for Medical Oncology [ESMO] and International Workshop on Chronic Lymphocytic Leukemia [iwCLL] recommended guidelines in assessing and treating chronic lymphocytic leukemia.

James Gerson, MD, discusses how he navigates treatment selection for patients with CLL and exciting developments in the pipeline.

January 13, 2021 - Health Canada has approved the combination of ibrutinib and rituximab for use in patients with treatment-naïve chronic lymphocytic leukemia.

As the coronavirus disease 2019 pandemic continues to pose challenges, health care providers struggle with decisions on how to balance the risk of severe acute respiratory syndrome coronavirus 2 transmission with the need to treat patients’ underlying conditions.